Diabetes Therapy Buzz: Recent chatter on social media has been ignited by Genprex, Inc.'s latest preclinical data for GPX-002, a gene therapy aimed at Type 2 diabetes. Many are thrilled about the reported success in normalizing glucose levels in animal studies. The potential for a groundbreaking treatment keeps the conversation lively.
Congressional Interest: Adding to the intrigue, social media discussions have noted a U.S. congressman’s recent purchase of Genprex shares. While some see this as a curious signal, others caution that it’s not a standalone reason for optimism. The stock’s volatile history continues to fuel debate.
Clinical Milestones: Talk also focuses on upcoming milestones, including FDA engagements slated for 2026. There’s palpable anticipation about how these developments might shape the company’s trajectory. Some express hope for accelerated progress in the diabetes therapy space.
Note: This discussion summary was generated from an AI condensation of post data.
Genprex, Inc. Congressional Stock Trading
Members of Congress have traded $GNPX stock 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GNPX stock by members of Congress over the last 6 months:
- REPRESENTATIVE TIM MOORE has traded it 3 times. They made 3 purchases worth up to $80,000 on 12/18, 11/07, 10/29 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Genprex, Inc. Hedge Fund Activity
We have seen 3 institutional investors add shares of Genprex, Inc. stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANE STREET GROUP, LLC added 205,180 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,737,874
- UBS GROUP AG removed 127,995 shares (-97.5%) from their portfolio in Q3 2025, for an estimated $21,682
- GEODE CAPITAL MANAGEMENT, LLC removed 71,923 shares (-95.6%) from their portfolio in Q3 2025, for an estimated $12,183
- VIRTU FINANCIAL LLC removed 43,103 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $7,301
- FREEDOM INVESTMENT MANAGEMENT, INC. removed 16,580 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,808
- HUB INVESTMENT PARTNERS, LLC removed 15,160 shares (-97.8%) from their portfolio in Q3 2025, for an estimated $2,568
- HIGHTOWER ADVISORS, LLC removed 14,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,371
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
